Viral infections associated with the clinical use of monoclonal antibodies

Clinical Microbiology and Infection

Volumn 17, Issue 12, 2011, Pages 1769-1775

  Gentile, G ^a   Foa R ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Immunosuppression; Infectious risks; Monoclonal antibodies; Outcome; Viruses

Indexed keywords

ACICLOVIR; ADALIMUMAB; ALEMTUZUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; ETANERCEPT; GANCICLOVIR; GOLIMUMAB; INFLIXIMAB; LAMIVUDINE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; TENOFOVIR; VALACICLOVIR; VALGANCICLOVIR; VINCRISTINE;

B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CRYOGLOBULINEMIA; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; EPSTEIN BARR VIRUS INFECTION; GRAFT VERSUS HOST REACTION; HEPATITIS B; HEPATITIS C; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; INFECTION PREVENTION; INFECTION RISK; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION;

CYTOMEGALOVIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPESVIRIDAE; HUMAN HERPESVIRUS 3; HUMAN HERPESVIRUS 4;

EID: 81255157515     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03680.x     Document Type: Review

References (54)

1. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
2. Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004; 10: 657-660.
3. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
4. Reddy JG, Loftus EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006; 35: 837-855.
5. Lok ASF, McMahon BJ. Chronic hepatitis B update 2009. Hepatology 2009; 50: 1-35.
6. Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies. Blood Rev 2008; 22: 117-126.
7. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113: 3147-3153.
8. Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 2011; 17: 1531-1537.
9. EASL. Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
10. Marzano A, Angelucci E, Andreone P et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
11. Loomba R, Rowley A, Wesley R et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-528.
12. Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of the novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic therapy. Gastroenterology 2006; 131: 59-68.
13. Yeo W, Steinberg JL, Tam JS et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999; 59: 263-269.
14. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
15. Torre D, Zeroli C, Giola M et al. Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin Infect Dis 1994; 18: 194-198.
16. Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 20-34.
17. Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9: 10-25.
18. Faguer S, Kamar N, Guilbeaud-Frugier C et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277-1280.
19. Aksoy S, Harputluoglu H, Kilickap S et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48: 1307-1310.
20. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 2011; 15: e2-e16.
21. Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611.
22. Raychaudhuri SP, Nguyen CT, Raychaudhuri SK, Gershwin ME. Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimm Rev 2009; 9: 67-81.
23. Ferri C, Govoni M, Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol 2010; 22: 443-450.
24. Ennishi D, Maeta Y, Niitsu N et al. Hepatic toxicity and prognosis in HCV-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010; 116: 5119-5125.
25. Ennishi D, Terui Y, Yokoyama M et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 2008; 83: 59-62.
26. Musto P, Dell'Olio M, La Sata A, Mantuano S, Cascavilla N. Diffuse B-large cell lymphomas (DBLCL) with hepatitis C virus (HCV) infection: clinical outcome and preliminary results of a pilot study combining R-CHOP with antiviral therapy. Blood 2005; 106: 688A.
27. CDC Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 2000; 49: 1-125.
28. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137: 435-478.
29. Bradford RD, Pettit AC, Wright PW et al. Herpes simplex encephalitis during treatment with tumor necrosis factor-α inhibitors. Clin Infect Dis 2009; 49: 924-927.
30. Strangfeld A, Listing J, Herzer P et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737-744.
31. Gentile G. Recent development in new and old viral infections. Rev Clin Exp Hematol 2005; 9: E3.
32. Capria S, Gentile G, Capobianchi A et al. Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute leukemia. J Med Virol 2010; 82: 1201-1207.
33. D'Ovidio V, Vernia P, Gentile G et al. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNF-alpha therapy. J Clin Virol 2008; 43: 180-183.
34. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2011; 6: 165-174.
35. Couriel D, Saliba R, Hicks K et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004; 104: 649-654.
36. Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009; 144: 818-831.
37. Thursky KA, Worth LJ, Seymour JF, Prince HM, Slavin MA. Spectrum of infection, risk and recommendation for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2005; 132: 3-12.
38. Vallejo C, Rios E, de la Serna J et al. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. Expert Rev Hematol 2011; 4: 9-16.
39. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006; 43: 16-24.
40. Chakrabartti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
41. Osteborg A, Foà R, Bezares RF et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009; 23: 1980-1988.
42. Osterborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H. Strategies in the management of alemtuzumab-related side effects. Semin Oncol 2006; 33 (suppl 5): S29-S35.
43. Ljungman P, de la Camara R, Milpied N et al. Randomized study of valaciclovir prophylaxis against cytomegalovirus reactivation in recipients of allogenic bone marrow transplantation. Blood 2002; 99: 3050-3056.
44. Lee MY, Chiou TJ, Hsiao LT et al. Rituximab therapy increased post-transplant cytomegalovirus complications in non-Hodgkin lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol 2008; 87: 285-289.
45. Heslop HH. How I treat lymphoproliferation. Blood 2009; 114: 4002-4008.
46. Peleg AY, Husain S, Kwak EJ et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44: 204-212.
47. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009; 48: 772-786.
48. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of the reported cases. Transpl Infect Dis 2009; 11: 383-392.
49. Papadopolous EB, Ladanyi M, Emanuel D et al. Infusion of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191.
50. Brown SE, Greene MH, Jershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-3158.
51. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-2895.
52. Scemla A, Loupy A, Candon S et al. Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: a case-controlled study. Transplantation 2010; 90: 1180-1184.
53. Thaunat O, Mamzer-Bruneel MF, Agbalika F et al. Severe huma herpesvirus-8 primary infection in a renal transplant patient successfully treated with anti-CD20 monoclonal antibody. Blood 2006; 197: 3009-3010.
54. Lavagna A, Bergallo M, Daperno M et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007; 13: 896-902.